P3 Research Ltd is a private company undertaking clinical trials in a wide variety of therapeutic areas, on behalf of international pharmaceutical and biotechnology companies. The company was formed in 2001 and initially had a single unit in Wellington. A second unit was opened in Tauranga in 2005 and a third in Havelock North, Hawke’s Bay in 2015. The sites each have stand-alone research facilities undertaking clinical trials in therapeutic areas, generally involving relatively prevalent and stable conditions normally managed in primary care. At any one time P3 is managing up to 40 clinical trials across its three units, some of which may be operating at 1, 2 or all 3 of it’s sites.
In addition to having conducted large numbers of phase 3 trials, P3 has particular experience and interest in early phase POC studies. All 3 units have facilities suitable for visits of up to 12 hours and the Wellington unit, which has 5 overnight beds, is available for studies requiring confinement for longer periods.
In addition to having conducted large numbers of phase 3 trials, P3 has particular experience and interest in early phase POC studies. All 3 units have facilities suitable for visits of up to 12 hours and the Wellington unit, which has 5 overnight beds, is available for studies requiring confinement for longer periods.